Table 3 Characteristics of patients with 2023 FIGO stage II EC stratified by hysterectomy type and surgical approach
Variables | Surgical scope | p-value | Surgical approach | p-value | ||
|---|---|---|---|---|---|---|
RH/mRH | SH | Laparoscope | Laparotomy | |||
n = 52 (%) | n = 28 (%) | n = 62 (%) | n = 18 (%) | |||
Age (years) |  |  | 0.711 |  |  | > 0.999 |
 < 65 | 44 (84.62) | 22 (78.57) |  | 51 (82.26) | 15 (83.33) |  |
 ≥ 65 | 8 (15.38) | 6 (21.43) |  | 11 (17.74) | 3 (16.67) |  |
Flushing fluid cytology | Â | Â | 0.888 | Â | Â | 0.628 |
 Negative | 44 (84.62) | 23 (82.14) |  | 53 (85.48) | 14 (77.78) |  |
 Positive | 3 (5.77) | 1 (3.57) |  | 3 (4.84) | 1 (5.56) |  |
 Deficiency | 5 (9.62) | 4 (14.29) |  | 6 (9.68) | 3 (16.67) |  |
Pathological type | Â | Â | 0.509 | Â | Â | 0.196 |
 Non-aggressive | 30 (57.69) | 14 (50.00) |  | 37 (59.68) | 7 (38.89) |  |
 Aggressive | 22 (42.31) | 14 (50.00) |  | 25 (40.32) | 11 (61.11) |  |
Histological grade | Â | Â | 0.459 | Â | Â | 0.225 |
 G1 | 20 (38.46) | 7 (25.00) |  | 23 (37.10) | 4 (22.22) |  |
 G2 | 11 (21.15) | 8 (28.57) |  | 16 (25.81) | 3 (16.67) |  |
 G3 | 21 (40.38) | 13 (46.43) |  | 23 (37.10) | 11 (61.11) |  |
Tumor diameter (cm) | Â | Â | 0.003 | Â | Â | 0.006 |
 <5 | 32 (61.54) | 26 (92.86) |  | 50 (80.65) | 8 (44.44) |  |
 ≥5 | 20 (38.46) | 2 (7.14) |  | 12 (19.35) | 10 (55.56) |  |
Invasion of the myometrium |  |  | 0.468 |  |  | > 0.999 |
 < 1/2 | 34 (65.38) | 16 (57.14) |  | 39 (62.90) | 11 (61.11) |  |
 ≥1/2 | 18 (34.62) | 12 (42.86) |  | 23 (37.10) | 7 (38.89) |  |
Invasion of cervical stroma | Â | Â | 0.005 | Â | Â | 0.123 |
 No | 24 (46.15) | 22 (78.57) |  | 39 (62.90) | 7 (38.89) |  |
 Yes | 28 (53.85) | 6 (21.43) |  | 23 (37.10) | 11 (61.11) |  |
LVSI | Â | Â | 0.277 | Â | Â | 0.018 |
 No | 23 (44.23) | 11 (39.29) |  | 22 (35.48) | 12 (66.67) |  |
 Focal | 17 (32.69) | 6 (21.43) |  | 18 (29.03) | 5 (27.78) |  |
 Universality | 12 (23.08) | 11 (39.29) |  | 22 (35.48) | 1 (5.56) |  |
P53 |  |  | > 0.999 |  |  | 0.722 |
 Wild type | 44 (84.62) | 23 (82.14) |  | 51 (82.26) | 16 (88.89) |  |
 Mutant type | 8 (15.38) | 5 (17.86) |  | 11 (17.74) | 2 (11.11) |  |
Ki67 index (%) | Â | Â | 0.451 | Â | Â | 0.747 |
 <70 | 25 (48.08) | 11 (39.29) |  | 29 (46.77) | 7 (38.89) |  |
 ≥70 | 27 (51.92) | 17 (60.71) |  | 33 (53.23) | 11 (61.11) |  |
Adjuvant chemotherapy | Â | Â | 0.116 | Â | Â | 0.911 |
 No | 15 (28.85) | 13 (46.43) |  | 21 (33.87) | 7 (38.89) |  |
 Yes | 37 (71.15) | 15 (53.57) |  | 41 (66.13) | 11 (61.11) |  |
Adjuvant radiotherapy | Â | Â | 0.342 | Â | Â | 0.710 |
 No | 37 (71.15) | 17 (60.71) |  | 43 (69.35) | 11 (61.11) |  |
 Yes | 15 (28.85) | 11 (39.29) |  | 19 (30.65) | 7 (38.89) |  |